The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) hit a new 52-week high and has $101.91 target or 57.00% above today’s $64.91 share price. The 5 months bullish chart indicates low risk for the $3.60 billion company. The 1-year high was reported on Sep, 30 by Barchart.com. If the $101.91 price target is reached, the company will be worth $2.05B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 326,141 shares traded hands. Nu Skin Enterprises, Inc. (NYSE:NUS) has risen 105.12% since February 26, 2016 and is uptrending. It has outperformed by 94.70% the S&P500.
Analysts await Nu Skin Enterprises, Inc. (NYSE:NUS) to report earnings on November, 3. They expect $0.83 EPS, down 1.19% or $0.01 from last year’s $0.84 per share. NUS’s profit will be $46.03M for 19.55 P/E if the $0.83 EPS becomes a reality. After $0.79 actual EPS reported by Nu Skin Enterprises, Inc. for the previous quarter, Wall Street now forecasts 5.06% EPS growth.
Nu Skin Enterprises, Inc. (NYSE:NUS) Ratings Coverage
Out of 9 analysts covering Nu Skin (NYSE:NUS), 3 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 33% are positive. $70 is the highest target while $34 is the lowest. The $55.29 average target is -14.82% below today’s ($64.91) stock price. Nu Skin has been the topic of 24 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, August 7 by Deutsche Bank. As per Thursday, July 30, the company rating was maintained by Canaccord Genuity. The firm has “Sell” rating by Stifel Nicolaus given on Wednesday, October 7. The rating was initiated by Jefferies on Friday, June 3 with “Hold”. On Friday, April 29 the stock rating was maintained by Pivotal Research with “Buy”. On Wednesday, October 7 the stock rating was maintained by Canaccord Genuity with “Hold”. The company was maintained on Wednesday, September 21 by Citigroup. The company was maintained on Friday, April 29 by Stifel Nicolaus. Pivotal Research maintained Nu Skin Enterprises, Inc. (NYSE:NUS) on Friday, August 5 with “Buy” rating. The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) earned “Sell” rating by Stifel Nicolaus on Friday, August 5.
According to Zacks Investment Research, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system.”
Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.03, from 1.04 in 2016Q1. The ratio is positive, as 30 funds sold all Nu Skin Enterprises, Inc. shares owned while 60 reduced positions. 36 funds bought stakes while 60 increased positions. They now own 40.71 million shares or 5.55% less from 43.10 million shares in 2016Q1.
Miles Cap Inc accumulated 0.65% or 20,626 shares. Vanguard last reported 4.31M shares in the company. Nomura Asset Mgmt owns 1,570 shares or 0% of their US portfolio. Palisade Capital Mngmt Ltd Nj last reported 0.04% of its portfolio in the stock. Aristotle Cap Boston Ltd Company reported 66,839 shares or 0.69% of all its holdings. Synovus Fincl holds 141 shares or 0% of its portfolio. Loudon Invest Limited Co owns 14,100 shares or 0.52% of their US portfolio. Blackrock Limited Liability Corporation holds 0% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS) for 31,071 shares. Ingalls Snyder has invested 0.15% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). 1832 Asset Mgmt L P, a Ontario – Canada-based fund reported 256,800 shares. Hsbc Hldg Public Ltd Co last reported 0% of its portfolio in the stock. Waddell & Reed Fincl Inc holds 396,000 shares or 0.04% of its portfolio. Bluemountain Management reported 15,172 shares or 0.02% of all its holdings. Finemark Comml Bank And Trust has invested 0% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). State Board Of Administration Of Florida Retirement System has 85,877 shares for 0.01% of their US portfolio.
Insider Transactions: Since September 22, 2016, the stock had 0 insider buys, and 1 insider sale for $1.92 million net activity. 30,000 shares were sold by LIPMAN ANDREW D, worth $1.92 million.
More notable recent Nu Skin Enterprises, Inc. (NYSE:NUS) news were published by: Fool.com which released: “Why Nu Skin Enterprises Inc. Stock Jumped 17% in June” on July 07, 2016, also Reuters.com with their article: “Skincare products maker Nu Skin settles SEC probe” published on September 20, 2016, Fool.com published: “Why Nu Skin Enterprises, Inc. Stock Popped Today” on June 16, 2016. More interesting news about Nu Skin Enterprises, Inc. (NYSE:NUS) were released by: Fool.com and their article: “Why Nu Skin Enterprises Inc. Stock Rose Today” published on August 05, 2016 as well as Finance.Yahoo.com‘s news article titled: “Zacks.com featured highlights: Regeneron Pharmaceuticals, Nordstrom, Intel, Nu …” with publication date: September 27, 2016.
NUS Company Profile
Nu Skin Enterprises, Inc., incorporated on September 4, 1996, is a global direct selling firm that develops and distributes personal care products and nutritional supplements, and a range of other services and products. The Firm offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Firm has activities in various geographic regions, including Greater China, North Asia, Americas, South Asia/Pacific, and Europe, the Middle East and Africa (EMEA). The Firm operates in the direct selling channel, primarily utilizing person-to-person marketing to promote and sell its products. The Firm offers Pharmanex nutritional supplements and Nu Skin personal care products under its ageLOC anti-aging brand. It also offers a limited number of other services and products, including household products and technology services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.